A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Dapagliflozin/saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 04 May 2023 Status changed from active, no longer recruiting to completed.
- 17 Jan 2023 Planned primary completion date changed from 15 Dec 2022 to 28 Feb 2023.
- 22 Sep 2022 Status changed from recruiting to active, no longer recruiting.